mGluRs: A target for pharmacotherapy in Parkinson disease

Jennifer A Feeley Kearney, Roger L. Albin*

*Corresponding author for this work

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Metabotropic glutamate receptors (mGluRs) are G-protein-coupled excitatory amino acid (glutamate) receptors and are abundantly expressed in basal ganglia nuclei. We used behavioral, regional glucose uptake metabolic mapping, and FOS protein expression to examine the effects of stimulating striatal and subthalamic mGluRs in rats. Stimulation of striatal Group I mGluRs produced behavioral effects mediated by polysynaptic activation of subthalamic neurons. Stimulation of subthalamic Group II mGluRs produced similar effects. Excessive activity of subthalamic neurons is a key feature of parkinsonism. mGluR Group I or Group II antagonists may prove to be useful for symptomatic treatment of parkinsonism. Stimulation of Group III mGluRs produced behavioral effects in only 6-hydroxydopamine-lesioned animals. Regional glucose uptake metabolic mapping and FOS expression studies suggested that striatal dopamine denervation produced increased sensitivity of Group III mGluRs. Agents active at Group III mGluRs may also be useful for treatment of parkinsonism.

Original languageEnglish (US)
Pages (from-to)30-36
Number of pages7
JournalExperimental Neurology
Volume184
Issue numberSUPPL. 1
DOIs
StatePublished - Nov 15 2003

Fingerprint

Metabotropic Glutamate Receptors
Parkinson Disease
Drug Therapy
Corpus Striatum
Glutamate Receptors
Parkinsonian Disorders
Basal Ganglia
Secondary Parkinson Disease
Neurons
Glucose
Oxidopamine
Denervation
GTP-Binding Proteins
Dopamine
Therapeutics

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

@article{ab0a4e8ef523462b900f7f1f422daf3d,
title = "mGluRs: A target for pharmacotherapy in Parkinson disease",
abstract = "Metabotropic glutamate receptors (mGluRs) are G-protein-coupled excitatory amino acid (glutamate) receptors and are abundantly expressed in basal ganglia nuclei. We used behavioral, regional glucose uptake metabolic mapping, and FOS protein expression to examine the effects of stimulating striatal and subthalamic mGluRs in rats. Stimulation of striatal Group I mGluRs produced behavioral effects mediated by polysynaptic activation of subthalamic neurons. Stimulation of subthalamic Group II mGluRs produced similar effects. Excessive activity of subthalamic neurons is a key feature of parkinsonism. mGluR Group I or Group II antagonists may prove to be useful for symptomatic treatment of parkinsonism. Stimulation of Group III mGluRs produced behavioral effects in only 6-hydroxydopamine-lesioned animals. Regional glucose uptake metabolic mapping and FOS expression studies suggested that striatal dopamine denervation produced increased sensitivity of Group III mGluRs. Agents active at Group III mGluRs may also be useful for treatment of parkinsonism.",
author = "Kearney, {Jennifer A Feeley} and Albin, {Roger L.}",
year = "2003",
month = "11",
day = "15",
doi = "10.1016/S0014-4886(03)00391-1",
language = "English (US)",
volume = "184",
pages = "30--36",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "SUPPL. 1",

}

mGluRs : A target for pharmacotherapy in Parkinson disease. / Kearney, Jennifer A Feeley; Albin, Roger L.

In: Experimental Neurology, Vol. 184, No. SUPPL. 1, 15.11.2003, p. 30-36.

Research output: Contribution to journalArticle

TY - JOUR

T1 - mGluRs

T2 - A target for pharmacotherapy in Parkinson disease

AU - Kearney, Jennifer A Feeley

AU - Albin, Roger L.

PY - 2003/11/15

Y1 - 2003/11/15

N2 - Metabotropic glutamate receptors (mGluRs) are G-protein-coupled excitatory amino acid (glutamate) receptors and are abundantly expressed in basal ganglia nuclei. We used behavioral, regional glucose uptake metabolic mapping, and FOS protein expression to examine the effects of stimulating striatal and subthalamic mGluRs in rats. Stimulation of striatal Group I mGluRs produced behavioral effects mediated by polysynaptic activation of subthalamic neurons. Stimulation of subthalamic Group II mGluRs produced similar effects. Excessive activity of subthalamic neurons is a key feature of parkinsonism. mGluR Group I or Group II antagonists may prove to be useful for symptomatic treatment of parkinsonism. Stimulation of Group III mGluRs produced behavioral effects in only 6-hydroxydopamine-lesioned animals. Regional glucose uptake metabolic mapping and FOS expression studies suggested that striatal dopamine denervation produced increased sensitivity of Group III mGluRs. Agents active at Group III mGluRs may also be useful for treatment of parkinsonism.

AB - Metabotropic glutamate receptors (mGluRs) are G-protein-coupled excitatory amino acid (glutamate) receptors and are abundantly expressed in basal ganglia nuclei. We used behavioral, regional glucose uptake metabolic mapping, and FOS protein expression to examine the effects of stimulating striatal and subthalamic mGluRs in rats. Stimulation of striatal Group I mGluRs produced behavioral effects mediated by polysynaptic activation of subthalamic neurons. Stimulation of subthalamic Group II mGluRs produced similar effects. Excessive activity of subthalamic neurons is a key feature of parkinsonism. mGluR Group I or Group II antagonists may prove to be useful for symptomatic treatment of parkinsonism. Stimulation of Group III mGluRs produced behavioral effects in only 6-hydroxydopamine-lesioned animals. Regional glucose uptake metabolic mapping and FOS expression studies suggested that striatal dopamine denervation produced increased sensitivity of Group III mGluRs. Agents active at Group III mGluRs may also be useful for treatment of parkinsonism.

UR - http://www.scopus.com/inward/record.url?scp=0242302346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242302346&partnerID=8YFLogxK

U2 - 10.1016/S0014-4886(03)00391-1

DO - 10.1016/S0014-4886(03)00391-1

M3 - Article

C2 - 14597323

AN - SCOPUS:0242302346

VL - 184

SP - 30

EP - 36

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - SUPPL. 1

ER -